Johnson & Johnson - Biotech Market Share Report

Johnson and Johnson market share report featuring Procrit and RemicadeCompany: Johnson & Johnson
2007 Sales: $6.2 billion
Market share: 8.4%
CAGR: 3%

What they have: J&J's bestselling biologic is Remicade ($3.3 billion). Like the other anti-TNFs on this list, Remicade is approved for treating a host of immune diseases including plaque psoriasis, rheumatoid arthritis, psoriac arthritis, adult Crohn's disease, pediatric Crohn's disease, ulcerative colitis and ankylosing spondylitis. The company's only other biotech blockbuster is Procrit, which rounded up $2.2 billion in 2007.

What to look for: Johnson & Johnson has filed two biologics for approval. The psoriasis treatment ustekinumab is on the verge of winning FDA approval, having been backed by an FDA expert committee. Golimumab--a human monoclonal antibody for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis--is also awaiting an FDA decision.

Johnson & Johnson - Biotech Market Share Report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.